Dermorphin
Dermorph
Dermorphin is a naturally occurring seven-amino acid opioid peptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) first isolated from the skin secretions of South American tree frogs of the genus Phyllomedusa. It is approximately 30-40 times more potent than morphine as a mu-opioid receptor agonist and contains the unusual D-alanine residue at position 2, making it one of the first discovered naturally occurring D-amino acid-containing peptides. It has gained notoriety for its illegal use in horse racing as a performance enhancer and pain masking agent.
Mechanism of Action
Naturally occurring heptapeptide isolated from the skin of South American tree frogs (Phyllomedusa). Potent and selective mu-opioid receptor agonist — approximately 30-40 times more potent than morphine. Contains D-alanine, which is rare in natural peptides.
Research Protocols
For research purposes only. Not medical advice.
Not recommended for human research due to extreme potency and opioid receptor agonism. Primarily of academic interest. Studied in pharmacological research for understanding mu-opioid receptor selectivity.
Research Notes
Clinical Research Status
Dermorphin has not been developed for human clinical use and has no active clinical trials or regulatory filings for any therapeutic indication. Research has been confined to pharmacological characterization, opioid receptor binding studies, and development of detection methods for equine anti-doping enforcement. It serves primarily as a research tool for understanding mu-opioid receptor pharmacology and the evolution of bioactive peptides in amphibian defense secretions.
Key Published Findings
Binding studies demonstrate that dermorphin has exceptionally high selectivity and affinity for mu-opioid receptors (Ki approximately 0.2-1.6 nM), significantly exceeding morphine in both potency and selectivity. The D-alanine residue at position 2 confers resistance to aminopeptidase degradation, extending its biological half-life compared to L-amino acid-containing endogenous opioid peptides. Research on dermorphin and its analogs has contributed significantly to understanding structure-activity relationships at the mu-opioid receptor and has led to development of several research tools for opioid pharmacology.
Safety Profile
As an extremely potent mu-opioid agonist, dermorphin carries all the risks associated with opioid intoxication including respiratory depression, profound sedation, physical dependence, and potentially fatal overdose. No therapeutic index has been established for humans, and the steep dose-response curve of highly potent opioids makes accidental overdose a significant risk. The absence of human pharmacokinetic data means that dosing, onset, duration, and drug interactions are completely unknown in clinical contexts.
Comparison to Related Compounds
Dermorphin is significantly more potent than morphine (30-40x) and fentanyl-like in its receptor binding affinity, though it maintains high mu-selectivity unlike some synthetic opioids that have broader receptor profiles. Its natural analog deltorphin (from the same frog species) is similarly potent but selective for delta-opioid receptors rather than mu-receptors. Compared to endogenous opioid peptides (endorphins, enkephalins), dermorphin's D-amino acid content provides superior metabolic stability and greater pharmacological potency.
Community Observations
Dermorphin is primarily known in the public sphere through horse racing scandals, where it has been detected in post-race urine samples from winning horses in multiple US states including Louisiana, Oklahoma, and New Jersey. Its use in horse racing is considered animal abuse by regulatory bodies, as it masks pain and allows injured horses to race at risk of catastrophic breakdown. Human recreational use is extremely rare due to limited availability and the extreme danger posed by its potency, with the research community treating it primarily as a pharmacological tool rather than a potential therapeutic.
Half-Life
~2-3 hours
Reconstitution
Sterile saline
Storage
Lyophilized
Store at -20C.
Reconstituted
Refrigerate 2-8C. Use within 7 days.
US Legal Status
Also Known As
PeptideVault provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.
Read full disclaimer